Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Valeo Pharma Inc T.VPH.DB


Primary Symbol: T.VPH Alternate Symbol(s):  VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler,... see more

Recent & Breaking News (TSX:VPH)

Valeo Pharma (TSX:VPH) partners with Novartis

Trevor Abes  August 2, 2022

VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS

Canada NewsWire August 2, 2022

VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®

Canada NewsWire August 2, 2022

VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA

Canada NewsWire August 2, 2022

VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS

Canada NewsWire June 14, 2022

VALEO PHARMA TO HOST SECOND QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire June 8, 2022

Valeo Pharma Inc. Opens the Market

Canada NewsWire May 9, 2022

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS

Canada NewsWire April 28, 2022

VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE

Canada NewsWire April 25, 2022

VALEO PHARMA ANNOUNCES LISTING OF CONVERTIBLE DEBENTURES ON TSX

Canada NewsWire April 19, 2022

VALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE

Canada NewsWire March 28, 2022

CSE Bulletin: Delist - Valeo Pharma Inc. (VPH, VPH.WT, VPH.WT.A)

Newsfile March 25, 2022

VALEO PHARMA REPORTS ITS FIRST QUARTER 2022 RESULTS AND HIGHLIGHTS

Canada NewsWire March 24, 2022

VALEO PHARMA SECURES ADDITIONAL PUBLIC REIMBURSEMENT FOR REDESCA(TM), ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®

Canada NewsWire March 22, 2022

VALEO PHARMA TO HOST FIRST QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST AND ATTEND THE 8TH ANNUAL ALPHANORTH CAPITAL CONFERENCE

Canada NewsWire March 17, 2022

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL 2021

Canada NewsWire February 28, 2022

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK

PR Newswire February 24, 2022

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2021 RESULTS CONFERENCE CALL / WEBCAST

PR Newswire February 21, 2022

VALEO PHARMA'S HESPERCO(TM) NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION

PR Newswire January 5, 2022

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA

PR Newswire December 15, 2021